Table 2

Study outcomes

OutcomesGroup A1, n = 88Group A2, n = 92Group B, n = 78P
Recurrences, no./total (%) 17/88 (19.3) 25/92 (27.2) 1/78 (1.3) .213 (A1 vs A2); .001 (A1 vs B); .001 (A2 vs B) 
Recurrences, no. per 100 person-years 10.1 15.2 0.63 .421 (A1 vs A2)*; .021 (A1 vs B)*; .001 (A2 vs B)* 
Type of recurrent VTE 
    DVT 17 25 1  
    DVT plus PE 0 0 0  
    Isolated PE 0 1† 0  
Contralateral 4 5 0  
Major bleeding, no./total (%) 2/88 (2.3) 1/92 (1.1) 0/78 (0) .534 (A1 vs A2)‡ 
Major bleeding, no. per 100 person-years 1.1 0.53 0 .685 (A1 vs A2)* 
OutcomesGroup A1, n = 88Group A2, n = 92Group B, n = 78P
Recurrences, no./total (%) 17/88 (19.3) 25/92 (27.2) 1/78 (1.3) .213 (A1 vs A2); .001 (A1 vs B); .001 (A2 vs B) 
Recurrences, no. per 100 person-years 10.1 15.2 0.63 .421 (A1 vs A2)*; .021 (A1 vs B)*; .001 (A2 vs B)* 
Type of recurrent VTE 
    DVT 17 25 1  
    DVT plus PE 0 0 0  
    Isolated PE 0 1† 0  
Contralateral 4 5 0  
Major bleeding, no./total (%) 2/88 (2.3) 1/92 (1.1) 0/78 (0) .534 (A1 vs A2)‡ 
Major bleeding, no. per 100 person-years 1.1 0.53 0 .685 (A1 vs A2)* 
*

Chi-square test for the comparison of 2 proportions, expressed as percentage.

†

PE was associated with an isolated distal DVT in the contralateral leg.

‡

P value refers to chi-square test unless specified.

View Large